Literature DB >> 26778839

Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.

E L Murphy1.   

Abstract

Many countries currently perform antibody screening for HTLV-1 infection in blood donors, and this intervention is likely cost-effective in preventing HTLV-1 related diseases in high prevalence countries. However, a number of high-income countries with low prevalence of HTLV-1 infection also perform universal HTLV-1 screening and debate has arisen regarding the cost-effectiveness of these strategies. Filter-based leukoreduction is likely to substantially reduce HTLV-1 transmission by removing infected lymphocytes, but actual laboratory data on its efficacy is currently lacking. Similarly, cost-effectiveness research on HTLV-1 prevention strategies is limited by poor data on prevalence, transmission efficacy and the cost of treating HTLV1 diseases.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Blood transfusion; Dépistage immunologique; HTLV-1; Immunoassay; Prevention and control; Prévention et contrôle; Transfusion sanguine

Mesh：

Year:  2016        PMID： 26778839      PMCID： PMC5042452          DOI： 10.1016/j.tracli.2015.12.001

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN： 1246-7820            Impact factor:   1.406


  43 in total

1.  Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation.

Authors:  O Gout; M Baulac; A Gessain; F Semah; F Saal; J Périès; C Cabrol; C Foucault-Fretz; D Laplane; F Sigaux
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

Review 2.  HTLV testing in blood transfusion.

Authors:  A M Couroucé; J Pillonel; J M Lemaire; C Saura
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

3.  Estimation of the infectious viral load required for transfusion-transmitted human T-lymphotropic virus type 1 infection (TT-HTLV-1) and of the effectiveness of leukocyte reduction in preventing TT-HTLV-1.

Authors:  R Sobata; C Matsumoto; S Uchida; Y Suzuki; M Satake; K Tadokoro
Journal:  Vox Sang       Date:  2015-04-30       Impact factor: 2.144

4.  Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction.

Authors:  Patricia E Hewitt; Katy Davison; David R Howell; Graham P Taylor
Journal:  Transfusion       Date:  2013-02-05       Impact factor: 3.157

5.  Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model.

Authors:  H Stigum; P Magnus; H H Samdal; E Nord
Journal:  Int J Epidemiol       Date:  2000-12       Impact factor: 7.196

6.  Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors.

Authors:  H H Lee; P Swanson; J D Rosenblatt; I S Chen; W C Sherwood; D E Smith; G E Tegtmeier; L P Fernando; C T Fang; M Osame
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

7.  Current prevalence of HTLV-1 in Japan as determined by screening of blood donors.

Authors:  Masahiro Satake; Kazunari Yamaguchi; Kenji Tadokoro
Journal:  J Med Virol       Date:  2012-02       Impact factor: 2.327

8.  Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period.

Authors:  V Massari; M H Elghouzzi; F Agis; C Rannou; E Gordien; D Costagliola; J J Lefrère
Journal:  Transfusion       Date:  1994-03       Impact factor: 3.157

9.  Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.

Authors:  Yun Brenda Chang; Zhanna Kaidarova; Daniel Hindes; Marjorie Bravo; Nancy Kiely; Hany Kamel; Denise Dubay; Barbara Hoose; Edward L Murphy
Journal:  J Infect Dis       Date:  2013-09-24       Impact factor: 5.226

10.  Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010.

Authors:  Shilpa Hakre; Mark M Manak; Clinton K Murray; Kenneth W Davis; Meera Bose; Aaron J Harding; Peter R Maas; Linda L Jagodzinski; Jerome H Kim; Nelson L Michael; Francisco J Rentas; Sheila A Peel; Paul T Scott; Sodsai Tovanabutra
Journal:  Transfusion       Date:  2013-01-30       Impact factor: 3.157
View more
  26 in total

Review 1.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

2.  Human T-cell lymphotropic virus type I and II seroprevalence among volunteer blood donors in Thailand.

Authors:  Sineenart Oota; Kriangsak Chaiwong; Soisaang Pikulsod; Rachanee Khuenkaew; Siriluk Pheakkhuntod; Pornthip Rattajak; Patcharakorn Kramkratok; Carlum Shiu; Sonu Bhatnagar; Tasanee Sakuldamrongpanich
Journal:  Pathog Glob Health       Date:  2018-11-14       Impact factor: 2.894

Review 3.  Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam; Reza Jafarzadeh Esfehani; Hiba El Hajj; Ali Bazarbachi
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

Review 4.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

5.  Molecular fusion events in carcinogenic organisms: a bioinformatics study for the detection of fused proteins between viruses, bacteria and eukaryotes.

Authors:  Eleni Papakonstantinou; Kalliopi Io Diakou; Thanasis Mitsis; Konstantina Dragoumani; Flora Bacopoulou; Vasilis Megalooikonomou; Sophia Kossida; George P Chrousos; Dimitrios Vlachakis
Journal:  EMBnet J       Date:  2022-04-04

Review 6.  Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond.

Authors:  Brian D Adkins; Juan C Ramos; Meghan Bliss-Moreau; Alejandro A Gru
Journal:  Semin Diagn Pathol       Date:  2019-12-20       Impact factor: 3.464

Review 7.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

8.  Evaluation of Sensitivity and Specificity Performance of Elecsys HTLV-I/II Assay in a Multicenter Study in Europe and Japan.

Authors:  Syria Laperche; Silvia Sauleda; Maria Piron; Annelies Mühlbacher; Harald Schennach; Volkmar Schottstedt; Lucinda Queirós; Naoki Uno; Katsunori Yanagihara; Roland Imdahl; Ariann Hey; Markus Klinkicht; Walter Melchior; Peter Muench; Toshiki Watanabe
Journal:  J Clin Microbiol       Date:  2017-05-03       Impact factor: 5.948

9.  Risk factors for HTLV-1 infection in Central Africa: A rural population-based survey in Gabon.

Authors:  Delia Doreen Djuicy; Augustin Mouinga-Ondémé; Olivier Cassar; Jill-Léa Ramassamy; Antony Idam Mamimandjiami; Rodrigue Bikangui; Arnaud Fontanet; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2018-10-12

10.  Revisiting human T-cell lymphotropic virus types 1 and 2 infections among rural population in Gabon, central Africa thirty years after the first analysis.

Authors:  Melanie Caron; Guillaume Besson; Cindy Padilla; Maria Makuwa; Dieudonne Nkoghe; Eric Leroy; Mirdad Kazanji
Journal:  PLoS Negl Trop Dis       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.